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Abstract 
 
Background:  Ado-trastuzumab emtansine (T-DM1) is an antibody-drug 
conjugate that does not cross an intact blood-brain barrier.  In the EMILIA trial 
of T-DM1 versus capecitabine/lapatinib for HER2 positive advanced breast 
cancer, all patients had baseline brain imaging, and 9/450 (2%) of patients 
with negative baseline imaging developed new brain disease during T-DM1. 
We assessed the frequency of brain progression in clinical practice, without 
routine baseline imaging. 
 
Methods:  A retrospective study of all patients treated with T-DM1 at the Royal 
Marsden Hospital from 2011-2016. Data collected included baseline 
characteristics, previous treatment for advanced breast cancer, sites of 
metastatic disease, duration of T-DM1, sites of progression and treatment of 
CNS progression. 
  
Results:  Fifty-five patients were identified who had received a median of 2 
prior lines of treatment (range 0-5). All were HER2 positive; 45 patients had 
IHC 3+ tumours and 10 were ISH positive. Patients received a median of 12 
cycles of T-DM1 (range 1-34), and 6 remain on treatment at the time of 
analysis.  Before commencing T-DM1, 16/55 (29%) had known brain 
metastases (treated with whole brain (9) stereotactic radiotherapy (6) or both 
(1)).  Brain was the first site of progression in 56% (9/16) patients, with a 
median time to brain progression of 9.9 months (95% CI 3.9-12.2).  
In patients without known baseline brain metastases, 17.9% (7/39) developed 
new symptomatic brain disease during T-DM1, after a median of 7.5 months 
(95%CI 3.8-9.6). Brain progression was isolated, with control of extra-cranial 
disease in 4/7 patients. Only one patient was suitable for stereotactic 
radiotherapy.  
Median time to extra-cranial progression in all patients was 11.5 months (95% 
CI 9.1-17.7), and median OS in all patients was 17.8 months (95% CI 14.2-
22).  
 
Conclusions:  In patients not screened for brain metastases at baseline, the 
brain was the first site of progression in a significant proportion.  Baseline 
brain imaging may have a role in standard practice for patients commencing 
T-DM1 therapy. 
 
 
Words=314 
Background 
 
 
T-DM1 is a novel antibody-drug conjugate combining a microtubule-inhibitory 
agent, emtansine (a derivative of maytansine) with the anti-HER2 antibody, 
trastuzumab. The EMILIA trial demonstrated that response rate, median 
progression-free survival (PFS) and median overall survival (OS) with T-DM1 
were superior to the prior standard of care, a combination of capecitabine and 
the dual EGFR/HER2 directed tyrosine kinase inhibitor (TKI), lapatinib, for 
previously treated HER2 positive advanced breast cancer [1]. T-DM1 is also 
superior to standard chemotherapy in patients who have received prior 
lapatinib [2]. The rate of CNS progression was not initially reported in either of 
these pivotal trials; however, CNS progression during trastuzumab is a well-
described clinical problem, occurring due to the extra-cranial efficacy of the 
agent leading to longer survival, combined with poor penetration of the CNS. 
In approximately half of patients with brain progression on trastuzumab, this 
occurs whilst the extra-cranial disease remains controlled [3], allowing local 
treatment of the brain disease (with surgery and/or radiotherapy) and 
continuation of trastuzumab in such patients. In a retrospective analysis of the 
EMILIA trial, for which baseline brain imaging was mandatory, 45/495 patients 
randomised to T-DM1 had brain metastases, which were untreated in 30%.  
CNS progression occurred in only 10 of these 45 patients (22.2%), with new 
CNS disease reported in just 9/450 patients with no CNS disease on baseline 
imaging (2%) [4], potentially suggesting CNS penetration and activity of T-
DM1 in patients whose disease or treatment has compromised the blood-
brain barrier.  A pre-clinical study has confirmed activity of T-DM1 in the brain 
microenvironment in trastuzumab-resistant cell cultures and mouse models [5], 
supporting these observations. 
 
In routine clinical practice, brain imaging to identify asymptomatic brain 
metastasis is frequently not conducted. We reviewed the incidence of 
symptomatic brain progressions in the absence of baseline imaging, to 
determine the frequency and timing of symptomatic CNS progression on T-
DM1 in a single institution.    
 
 
Methods 
 
Study design 
This retrospective study was initiated with the primary objective of determining 
the frequency of brain progression in patients with advanced HER2 positive 
breast cancer receiving T-DM1. Secondary endpoints comprised the timing of 
brain versus extra-cranial progression, the relative frequency of parenchymal 
and leptomeningeal brain disease in this patient group, and the progression-
free and overall survivals in the sub-groups of patients with known brain 
metastases, those who developed symptomatic brain disease during therapy 
and patients without diagnosed CNS disease. 
 
Patients 
Eligible patients who received at least one cycle of T-DM1 for HER2 positive 
advanced breast cancer between January 1st 2011 and January 1st 2016 were 
identified from the Royal Marsden Hospital Pharmacy database.  The data 
cut-off date was 13th July 2016. 
Hormone receptor positive was defined as an oestrogen and/or progesterone 
receptor Allred score of 3/8 or greater.  HER2 positive was defined as HER2 
3+ positive by IHC, or an in situ hybridisation (ISH) ratio >2.0, or an absolute 
HER2 copy number of ≥ 6 also defined HER2 positivity regardless of ratio, as 
per ASCO/CAP guidelines [6]. Data were collected from the electronic patient 
record on gender, age, breast cancer histology, receptor status, prior 
treatment for advanced breast cancer, sites of disease, prior local treatment 
for brain metastases, number of cycles of T-DM1, best response to T-DM1, 
dates of brain and extra-cranial progression, type of brain progression, 
treatment of CNS progression and date of death or last follow-up.  
Surveillance brain imaging was performed approximately every 3 months in 
patients with known brain metastases. 
 
Statistical Methods 
In patients with and without known brain disease at baseline, time to central 
nervous system (CNS) progression was defined from start of treatment with T-
DM1 to date of any CNS progression. Any CNS progression-free patients 
were censored at last follow up.   
Time to extra-cranial progression was also calculated in patients with and 
without CNS progression from date of 1st T-DM1 infusion to date of extra-
cranial progression. Kaplan Meier methods were used to calculate time to 
extra cranial progression.  
CNS Response rate was assessed only in patients with known CNS disease 
prior to commencing T-DM1. This is presented as a proportion with the 95% 
confidence interval.   The relative frequency of parenchymal versus 
leptomeningeal versus mixed CNS disease developing on T-DM1 was 
assessed only in patients without known CNS disease prior to T-DM1.  
Progression-free survival was calculated in all patients from date of 1st T-DM1 
infusion to date of a) any progression and b) non-CNS progression using 
Kaplan-Meier methods.  Overall survival was calculated from date of 1st T-
DM1 infusion using Kaplan-Meier methods, surviving patients were censored 
at date of last follow-up.  
 
 
Results 
 
 
Fifty-five patients were treated with T-DM1 with a median duration of follow-up 
of 20.5 months. Baseline demographics are summarised in table 1. The 
majority of patients (30/55, 54.5%) had received at least 2 prior lines of 
treatment for advanced breast cancer, although T-DM1 was first-line therapy 
in 10/55 (18.2%) who had relapsed on or within 6 months of completing 
adjuvant trastuzumab. Twenty-seven patients (49.1%) had received prior 
lapatinib, but only 8 (14.5%) had been exposed to pertuzumab, reflecting the 
timing of our study relative to licensing of pertuzumab in Europe in 2013. 
Patients received a median of 12 cycles of T-DM1 (range 1-34 cycles). 
 
Patients with brain disease prior to T-DM1 
Sixteen patients (29.1%) had known brain involvement at baseline, with 
parenchymal metastases in all patients, one with additional leptomeningeal 
involvement reported on MRI. All patients had received prior local therapy to 
the brain; with whole brain radiotherapy (WBRT) in 10 patients (62.5%), and 
stereotactic radiotherapy (RT) without WBRT in 6 patients (37.5%), of whom 
2/6 also underwent neurosurgery. One of the 16 patients (6.25%) had 
untreated brain progression (leptomeningeal progression after prior 
stereotactic RT) at the time of starting T-DM1.   
 
None of the 13 assessable patients had radiological responses in the brain to 
T-DM1; two patients were not assessable due to death after one cycle of T-
DM1, a 3rd did not have any follow-up brain imaging during T-DM1. The brain 
was the first site of progression in 9/16 patients (56.3%), although two had 
concurrent extra-cranial progression. A further two patients developed brain 
progression during subsequent lines of therapy, 2 and 8 months after 
completing T-DM1, and a third patient died with progressive neurological 
symptoms with no radiological confirmation of CNS progression.  Treatment 
for brain progression was WBRT in five of the 16 patients (31.3%), 
stereotactic RT in three (18.8%) and no brain-directed therapy in 8 (50%).  
The median time to brain progression in these 16 patients was 9.9 months 
(95% confidence interval (CI) 3.9-12.2 months). The median OS was 15.3 
(95% CI 4.7-Not reached) months in patients with known brain disease at 
baseline 
 
Patients without known brain disease prior to T-DM1 
The remaining 39 patients (70.9%) were not known to have brain disease on 
commencing T-DM1, with routine brain imaging not performed in 
asymptomatic patients. Three of the 39 patients had undergone an MRI brain 
within a month prior to starting T-DM1 to investigate symptoms, which showed 
no evidence of disease in all 3.  During treatment with T-DM1, 7/39 patients 
(17.9%) developed symptomatic CNS disease, parenchymal brain metastases 
in 5 patients and leptomeningeal disease in 2 patients. Three of the 7 patients 
(42.9%) had extra-cranial progression diagnosed concurrently. Five of the 7 
patients underwent WBRT (71.4%), one was suitable for stereotactic RT 
(14.3%) and one received no brain-directed therapy (14.3%). 
A further three patients developed symptomatic brain progression, 4, 7 and 15 
months respectively after completing T-DM1 for extra-cranial progression, two 
of whom received WBRT. 
 
The median time to brain progression in the 7 patients without known brain 
disease prior to T-DM1, who then developed symptomatic CNS progression 
during this treatment was 7.5 months (95%CI 3.8-9.6 months). Table 2 reports 
the time to brain progression for patients with brain disease at baseline, 
compared to those who developed brain disease on T-DM1. Figure 1 shows 
the time to brain progression (1A) and extra-cranial progression (1B) in all 
patients, by baseline brain disease status. The median OS of patients who 
developed brain disease during T-DM1 was 12.4 (95% CI 10.5-17.8) months, 
compared to 22 months in patients without brain disease before or during T-
DM1 (95% CI 15.1-Not reached).   The median OS from diagnosis of new 
CNS disease was 5.7 months (95% CI 0.9-12.0). 
 
CNS haemorrhage 
Three of the 23 patients (13.0%) with baseline or new brain disease 
developed significant intra-cranial haemorrhage associated with parenchymal 
brain metastases whilst on T-DM1. This was the first presentation of brain 
disease in one patient, and occurred within a new metastasis in the second 
patient who had multiple pre-treated metastases; both haemorrhages were 
terminal events.  The third patient underwent craniotomy and removal of a 
previously stereotactic RT-treated parietal lobe metastasis which had become 
haemorrhagic, with good recovery. 
 
Efficacy of T-DM1 in all patients 
At the time of analysis, 23/55 patients were alive, ten of whom remained on T-
DM1. Four of 51 evaluable patients (7.8%) had a complete response to T-
DM1, of whom three remain in complete remission on treatment at median 18 
months follow-up; the fourth died from neurological complications of radiation 
necrosis.   A further 14 patients had a partial response (PR), giving an overall 
response rate of 35.3% (95% CI: 22.4 – 49.9).  Four patients were not 
evaluable for response due to death before response evaluation scans in 2 
patients, early cessation of T-DM1 for toxicity in 1 patient and no extra-cranial 
disease in 1.  
The median time to extra-cranial progression in all patients was 11.5 months 
(95% CI 9.1-17.7 months), shown in figure 2A, and median OS in all patients 
was 17.8 months (95% CI 14.2-22 months), figure 2B.   Figure 3 shows the 
overall survival by brain disease status. 
Figure 4 summarises CNS and extra-cranial outcomes during T-DM1. 
 
 
 
Discussion 
 
In this single institution experience of T-DM1, without mandatory baseline 
brain imaging, we report a higher than expected rate of brain progression, in 
patients without known brain involvement (17.9%), as well as in patients with 
known pre-treated brain disease. The survival in patients presenting with new 
brain disease during TDM1 was particularly poor in our study. Interestingly, 
4/7 (57.1%) of these patients had associated extra-cranial progression.  All 
but one patient received brain-directed therapy, which was WBRT in 5, but 
only one patient was suitable for stereotactic RT (defined in the UK National 
Health Service since 2013 as calculated disease volume less than 20CC) and 
median time from diagnosis of CNS disease to death was 5.7 months.  
 
No radiological responses in the brain were reported in our study, possibly a 
reflection of prior brain treatment in all 16 patients, only one of whom had 
progressing disease at commencement of T-DM1. In contrast, a study of 
patients with untreated (n=2) or progressing (n=8) brain metastases, reported 
three partial responses to T-DM1, including one in an untreated brain, with a 
median intra-cranial PFS of 5 months [7]. A recently published case series of 
39 patients with brain metastases treated with T-DM1 reported a median time 
to brain progression of 8.6 months, with progression in the brain occurring as 
the first site of progression in 19 patients (48.7%), of whom only 3 had 
concurrent extra-cranial progression [8]. Similar to our study population, these 
patients had received a median of 2 prior lines of chemotherapy for advanced 
breast cancer, but in contrast, all patients had progressive brain disease when 
they commenced T-DM1.  Despite this, their rate of brain progression on T-
DM1 is similar to the rate (9/16, 56.3%) we report here in the 16 patients with 
known brain metastases, for whom the median brain-specific PFS was 9.9 
months. Taken together, these results suggest that T-DM1 may have 
contributed to the control of brain disease in the 7/16 patients without brain 
progression in our trial, as their outcome was similar to patients with untreated 
brain disease in the French series. CNS penetration by T-DM1 is presumed to 
result from disruption of the blood brain barrier by the disease and/or its 
treatment. 
 
The retrospective analysis of the EMILIA trial [4] is the largest available series 
of brain events in patients treated with T-DM1, reporting brain progression in 
16% of patients with known brain disease and 2% of those with no brain 
disease on baseline imaging.  The lack of baseline brain imaging in standard 
practice is an important difference between our population and that in the 
EMILIA trial, and may explain the higher rate of new brain disease diagnosed 
during treatment. All patients in our study population had required previous 
local therapy to the brain due to symptomatic presentation, potentially 
reflecting a higher burden of brain disease in our population.  Ours was also a 
more heavily pre-treated group, closer to the TH3RESA trial population [2], 
and the median OS of 17.8 months in our study is comparable to the 22.7 
months in TH3RESA,[9] but not to the 30.9 months in EMILIA. This may also 
explain the higher rate of brain progression in patients without known brain 
disease in our study compared to EMILIA. 
Arguably, the poor survival in patients developing symptomatic brain disease 
during T-DM1 therapy requires intervention. One approach would be 
consideration of prophylactic cranial irradiation (PCI), a strategy employed in 
extensive stage small cell lung cancer, which prolongs median overall survival 
in this poor prognosis disease [10]. However, with the prolonged survival now 
expected for HER2 positive advanced breast cancer patients [11], and brain 
metastases being a common but not inevitable complication of this disease, it 
seems inappropriate to expose all patients receiving T-DM1 to the morbidity 
from PCI.  Co-treatment with a HER2-directed TKI would be an alternative 
strategy: The anti-HER2 TKI lapatinib has central nervous system activity, 
with a 6% brain response rate with monotherapy and 20% response rate with 
capecitabine reported in a phase II trial [12]. Combination of lapatinib with T-
DM1 and nab-paclitaxel in HER2-positive advanced breast cancer (including 
patients with brain metastases) is currently being investigated in a phase I/II 
trial (NCT02073916). Modest brain activity has also been reported for the 
pan-HER TKI, neratinib, with an 8% response rate in a small (n=40) phase II 
study [13], leading to ongoing trials of this agent in combination with 
chemotherapy.  Combination of neratinib with T-DM1 is also under 
investigation, although patients with symptomatic brain metastases are 
unfortunately excluded from this phase I/II trial (NCT02236000). A selective 
anti-HER2 TKI, tucatinib (ONT-380), showed promising CNS activity in 
combination with T-DM1 in a phase Ib study which has been presented, but 
not yet published: The authors reported brain responses in 4 of the 12 
patients with measurable brain disease and a further 5 patients had disease 
stabilisation from the combination, which appeared well-tolerated [14].  
A more conservative approach would be routine brain imaging in 
asymptomatic patients starting T-DM1, contrary to current ASCO guidelines 
for HER2 positive breast cancer[15].  This could allow early intervention with 
stereotactic brain RT, potentially avoiding the unnecessary cognitive morbidity 
of WBRT, or systemic toxicity from a TKI. A randomised study investigated 
the neurocognitive impact of WBRT added to stereotactic RT in patients with 
1-3 brain metastases (8.5% breast cancer) and reported better quality of life in 
patients randomised to stereotactic RT alone, although the time to intracranial 
failure was shorter than in patients who additionally received WBRT [16]. This 
may also be the case for patients with multiple metastases, although 
randomised data are lacking; a large observational study of stereotactic brain 
RT, for patients (10% breast cancer) with up to 10 brain metastases, reported 
similar outcomes to patients with 1-3 metastases, suggesting that avoiding the 
morbidity from WBRT is an alternative, even when brain disease is multifocal 
[17]. Median survivals of 20-26 months for patients with HER2 positive breast 
cancer brain metastases selected for stereotactic radiosurgery has been 
reported in several studies [18-20], therefore this is also an effective treatment 
for this patient subgroup. 
CNS haemorrhage has been previously reported in patients with previously 
irradiated brain metastases receiving T-DM1 despite (near) normal platelet 
counts,[21] and may be due to enhancement of radiation necrosis.  
Importantly, such cases may be amendable to neurosurgical resection[22]. On 
pathological examination, telangiectasia have been observed; a finding 
previously reported at extra-cranial sites in patients receiving T-DM1[23, 24]. 
One of the three cases we report was in a previously irradiated lesion and 
was successfully treated surgically.  Two cases occurred in association with 
new brain metastases, one patient was anti-coagulated with warfarin and had 
chronic grade 1 thrombocytopenia due to T-DM1, the second developed 
grade 2 thrombocytopenia immediately before the haemorrhage, but an 
association with T-DM1-related telangiectasia cannot be excluded as no 
neurosurgical intervention was attempted for either case. 
 
Conclusions 
 
In our study, the development of new brain disease on T-DM1 was more 
common than previously reported, and survival from diagnosis with 
symptomatic progression was poor. Larger, prospective studies are required 
to determine whether baseline brain imaging prior to commencing T-DM1 is 
indicated to identify asymptomatic brain disease that can be treated with 
stereotactic radiotherapy, or surgery.  Residual disease may be treated 
effectively by T-DM1, potentially allowing avoidance or at least deferral of 
whole brain radiotherapy and its complications. 
 
 
Table 1 Baseline characteristics 
 
 Patients (%) 
N=55 
Gender: Female 55 (100%) 
Median age 
(range) 
57.0 years 
(26-82) 
Histological subtype: 
-Ductal 
-Lobular 
-Unknown 
 
45 (81.8%) 
3 (5.5%) 
7 (12.7%) 
Receptor Status 
-Hormone receptor positive 
-Hormone receptor negative 
 
35 (63.6%) 
20 (36.4%) 
Median number of lines of treatment for 
advanced breast cancer 
(range) 
 
2 
(0-6) 
Prior lapatinib 27 (49.1%) 
Prior pertuzumab 8 (14.5%) 
Sites of metastatic disease: 
-Bone 
-Visceral 
-Brain 
 
36 (65.5%) 
44 (80.0%) 
16 (29.0%) 
Type of brain disease 
-Parenchymal 
-leptomeningeal (LM) 
-mixed 
-none 
 
15 (27.3%) 
0 
1 (1.8%) 
39 (70.9%) 
Prior treatment to brain disease: 
-Stereotactic RT  
-Whole brain RT  
-Stereotactic + whole brain RT 
-Surgery and stereotactic RT 
 
4/16 (25.0%) 
9/16 (56.3%) 
1/16 (6.3%) 
2/16 (12.5%) 
RT=Radiotherapy 
Table 2 Brain disease, treatment and outcomes 
 
 Patients with 
baseline brain 
metastases 
N=16 
Patients with 
development of LMD 
and/or brain metastases 
during T-DM1 
N=7 
Type of brain disease on 
progression: 
-parenchymal only 
-Leptomeningeal only 
-No progression 
 
 
5 (31.3%) 
4 (25.0%) 
7 (43.8%) 
 
 
5 (71.4%) 
2 (28.6%) 
- 
Treatment of brain 
progression during T-
DM1: 
-Local therapy 
 -Whole brain RT 
 -Stereotactic RT 
-None 
-Systemic therapy 
-No progression 
 
 
 
5 (50%) 
2 (12.5%) 
3 (18.8%) 
3 (18.8%) 
1 (6.3%) 
7 (43.4%) 
 
 
 
6 (85.7%) 
 -5 (71.4%) 
 -1 (14.3%) 
1 (14.3%) 
0 
Not applicable 
Median time to CNS 
progression (95% CI)  
9.9 months (3.9-12.2) 7.5 months (3.8-9.6) 
Median OS (95% CI) 15.3 months (4.7-not 
reached) 
12.4 months (10.5-17.8) 
RT=radiotherapy 
 
 
Figure 1A Time to brain progression in all patients by baseline CNS disease status 
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Figure 1B Time to extracranial disease progression in all patients by baseline 
CNS status 
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Figure 2A. Time to extra-cranial disease progression in all patients 
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Figure 2B:  Overall survival in all patients  
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Figure 3: Median Survival in patients by CNS status: 
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Figure 4. Patient flow diagram 
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